{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T13:06:04Z","timestamp":1779541564013,"version":"3.53.1"},"reference-count":33,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T00:00:00Z","timestamp":1773532800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T00:00:00Z","timestamp":1773532800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pediatric Blood &amp;amp; Cancer"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The United Kingdom relapsed Wilms tumour (UKW\u2010R) trial aimed to improve the historically low survival rates after relapse of Wilms tumour (WT) through a prospective national risk\u2010stratified protocol. The trial also evaluated efficacy and toxicity of high\u2010dose melphalan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with relapsed\/refractory WT were allocated to one of three treatment groups based on time to relapse and initial therapy. Group A: Patients with Stage 1 non\u2010anaplastic WT treated only with vincristine (VCR) or up to two doses of VCR + actinomycin D (ACT) relapsing &gt; 6 months from diagnosis received \u2018intensive\u2019 AVD (ACT + VCR + doxorubicin [DOX]). Group B: Patients with Stage 2 non\u2010anaplastic WT treated with VCR + ACT relapsing &gt; 6 months from diagnosis received eight alternating courses of DOX\/cyclophosphamide (CPM) and CPM\/etoposide (ETOP). Group C: All other patients whose initial therapy included additional DOX, other drugs and\/or radiotherapy received six alternating courses of carboplatin (CARBO)\/ETOP and CPM\/ETOP followed by melphalan + autologous stem cell rescue (M + ASCT). All patients were recommended radiotherapy \u00b1 surgery for sites of relapse.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>From 2002 to 2008, 78 children were enrolled (Group A: 13, Group B: 10 and Group C: 55). Median age was 5.3 years. 38 children received M + ASCT with no transplant related mortality. 25 children died (5: Group A + B and 20: Group C), all from tumour related causes. The 4\u2010year event\u2010free and overall survival for the whole group were 63% and 68%, and 77%\/81% (Group A + B) and 57%\/63% (Group C), respectively. Median follow\u2010up for alive patients is 65.4 months (8.1\u2013155.4).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Survival rates following risk stratification including M + ASCT are higher than historical observations for similar high\u2010risk groups that did not include high\u2010dose chemotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/1545-5017.70191","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T06:23:11Z","timestamp":1773642191000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Results of the Childhood Cancer and Leukaemia Group's United Kingdom Relapsed Wilms Tumour Trial"],"prefix":"10.1002","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2980-9316","authenticated-orcid":false,"given":"Sucheta J.","family":"Vaidya","sequence":"first","affiliation":[{"name":"Paediatric Oncology The Royal Marsden NHS Foundation Trust  London UK"},{"name":"Division of Clinical Studies The Institute of Cancer Research  Sutton London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Moroz","sequence":"additional","affiliation":[{"name":"Cancer Research UK Clinical Trials Unit (CRCTU) University of Birmingham  Birmingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliet","family":"Hale","sequence":"additional","affiliation":[{"name":"Paediatric Oncology University of Newcastle Upon Tyne  Newcastle UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vesna","family":"Pavasovic","sequence":"additional","affiliation":[{"name":"Paediatric Oncology Great Ormond Street Hospital for Children  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Hobson","sequence":"additional","affiliation":[{"name":"Clinical Trials Unit University of Leicester  Leicester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Sartori","sequence":"additional","affiliation":[{"name":"Paediatric Palliative Medicine Cambridge University Hospitals NHS Foundation Trust  Cambridge UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Saunders","sequence":"additional","affiliation":[{"name":"Clinical Oncology The Christie NHS Foundation Trust  Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Powis","sequence":"additional","affiliation":[{"name":"Paediatric Surgery Leeds Teaching Hospitals NHS Trust  Leeds UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordan M.","family":"Vujanic","sequence":"additional","affiliation":[{"name":"Department of Pathology Sidra Medicine  Doha Qatar"},{"name":"Weill Cornell Medicine \u2013 Qatar  Doha Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Baker","sequence":"additional","affiliation":[{"name":"Cancer Research UK Clinical Trials Unit (CRCTU) University of Birmingham  Birmingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Pritchard\u2010Jones","sequence":"additional","affiliation":[{"name":"Paediatric Oncology University College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,3,15]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds025"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.06.007"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(14)62395\u20103"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(18)30293\u20106"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.6190.567"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.1.124"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2000.1338"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2006.05.026"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/adc.65.9.968"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19910201)67:3<567::AID-CNCR2820670307>3.0.CO;2-2"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.5.638"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.8.1478"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1988.6.5.793"},{"issue":"9","key":"e_1_2_8_15_1","first-page":"815","article-title":"Phase II Trail Cisplatin in Refractory Childhood Cancer: Children's Cancer Study Group Report","volume":"65","author":"Baum E. S.","year":"1981","journal-title":"Cancer Treatment Reports"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.5.931"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.2950250103"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0031\u20103955(16)34834\u20109"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf028"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/0022-3468(91)90021-K"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.2950220103"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.10.3295"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1055\/s\u20102008\u20101046471"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21524"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(96)00075-X"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.20822"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.12.014"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21267"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/00043426\u2010200203000\u201000007"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.09.073"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.07.010"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2017.178"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409\u2010019\u20100661\u20107"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2017.163"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/1545-5017.70191","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/1545-5017.70191","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/1545-5017.70191","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T12:28:07Z","timestamp":1779539287000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/1545-5017.70191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,15]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1002\/1545-5017.70191"],"URL":"https:\/\/doi.org\/10.1002\/1545-5017.70191","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,15]]},"assertion":[{"value":"2025-03-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70191"}}